Oman Investment Authority disclosed a strategic investment in Neuralink Corporation, Elon Musk's brain-computer interface developer, without naming the valuation or check size. The placement marks the first known Gulf sovereign participation in the neurotechnology sector at venture scale.

Neuralink last raised at a $5 billion valuation in private secondary transactions during 2024, according to pricing data from forfeited employee share sales. The company received FDA approval for its second human implant trial in May 2024 and has since implanted devices in three patients. Oman's entry follows pattern investments the fund has made in SpaceX and xAI, both Musk-controlled entities, suggesting coordinated exposure to the founder's portfolio rather than isolated sector conviction.

The timing is clinical. Neuralink requires $150 million to $200 million annually in operational burn to fund trials, hardware iteration, and FDA navigation, per estimates derived from hiring velocity and facility footprint. Sovereign backing provides runway without the valuation pressure of traditional venture rounds. More importantly, it positions Oman—population 4.5 million, GDP $115 billion—as an early holder in a category where exits are measured in decades and strategic acquirers are nonexistent. Brain-computer interfaces sit outside the venture model. They require patient, non-mark-to-market capital willing to absorb regulatory risk and long commercialization arcs.

Gulf sovereigns are moving earlier. UAE's Mubadala entered Anthropic at $18 billion in early 2024. Saudi PIF participated in SoftBank's $100 billion AI infrastructure joint venture announced in December. Oman, smaller and historically conservative, is now layering venture exposure atop its traditional energy and infrastructure mandates. The shift reflects two forces: dollar diversification away from Treasury concentration and recognition that compute, biotech, and defense converge in the same companies. Neuralink threads all three.

Allocators should track FDA milestone disclosures through Q2 2025, when Neuralink is expected to file for expanded trial authorization involving motor function restoration. Sovereign follow-on appetite will surface in any Series C or growth round, likely $300 million to $500 million, should the company formalize institutional capital before attempting device commercialization in 2027. Any Musk portfolio cross-holdings—SpaceX Starlink integration, Tesla Optimus synergies—will appear in infrastructure contracts Oman negotiates separately.

Neuralink's device transmitted 1,024 channels of neural data in its second patient trial, double the first. The company is not selling hope. It is selling bandwidth.